KLAC
45
3
TAP
57
6
NEM
30
2
DTE
49
16
VFC
56
6
PNR
56
2
PX
56
3
LB
16
9
FSLR
50
6
DVA
62
5
TXT
46
4
PCG
59
9
OI
23
3
KR
50
5
HIG
48
5
ILMN
31
4
DOW
47
4
IVZ
42
13
ABT
54
4
AEE
51
3
KLAC
45
3
TAP
57
6
NEM
30
2
DTE
49
16
VFC
56
6
PNR
56
2
PX
56
3
LB
16
9
FSLR
50
6
DVA
62
5
TXT
46
4
PCG
59
9
OI
23
3
KR
50
5
HIG
48
5
ILMN
31
4
DOW
47
4
IVZ
42
13
ABT
54
4
AEE
51
3
Financhill
Back

Alnylam Pharmaceuticals 10K Form

Sell
27

ALNY
Alnylam Pharmaceuticals

Last Price:
$245.56
Seasonality Move:
2.78%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2024-05-02 10Q ALNY/Alnylam Pharmaceuticals Quarterly
2023-11-02 10Q ALNY/Alnylam Pharmaceuticals Quarterly
2023-08-03 10Q ALNY/Alnylam Pharmaceuticals Quarterly
2023-05-04 10Q ALNY/Alnylam Pharmaceuticals Quarterly
2022-10-27 10Q ALNY/Alnylam Pharmaceuticals Quarterly
2022-07-28 10Q ALNY/Alnylam Pharmaceuticals Quarterly

Receive ALNY News And Ratings

See the #1 stock for the next 7 days that we like better than ALNY

ALNY Financial Statistics

Sales & Book Value

Annual Sales: $1.8B
Cash Flow: $39.5M
Price / Cash Flow: 1937.51
Annual Sales: $0.25
Price / Book: 978.7

Profitability

EPS (TTM): -2.62000
Net Income (TTM): $-332.3M
Gross Margin: $1.5B
Return on Equity: 0%
Return on Assets: -8.43%

Alnylam Pharmaceuticals Earnings Forecast

Key Alnylam Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 19 years for ALNY is 83.02%.
  • The Selling, General & Administrative Expenses for ALNY have been equal to 43.52% of Gross Profit Margin.
  • The Research & Development expenses have been 54.94% of Revenue.
  • The Interest Expense is -27.54% of Operating Income.
  • The Net Earning history of ALNY is -24.08% of Total Revenues.
  • Per Share Earnings over the last 22 years have been positive in 10 years.

Alnylam Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: ALNY
CUSIP: 02043Q
Website: alnylam.com

Debt

Debt-to-Equity Ratio: 31.64
Current Ratio: 2.75
Quick Ratio: 2.57

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 472.37

ALNY Technical Analysis vs Fundamental Analysis

Sell
27
Alnylam Pharmaceuticals (ALNY) is a Sell

Is Alnylam Pharmaceuticals a Buy or a Sell?